Elanco s Varenzin-CA1 is the first drug for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats for which the Food and Drug Administration (FDA) has granted conditional approval, the agency announced May 1. Varenzin-CA1 is available only by prescription from a licensed veterinarian.
Varenzin-CA1 from Elanco is the first drug used by veterinarians or animal owners. Varenzin-CA1 is available only by prescription from a
First Approval for Cats Under Conditional Approval Pathway Today, the U.S. Food and Drug Administration conditionally approved Varenzin-CA1 (
Varenzin -CA1 Oral Suspension is a once-daily oral option that safely treats non-regenerative anemia in cats with chronic kidney disease (CKD). Varenzin-CA1 Oral Suspension (Rx)
The use of Varenzin-CA1 administered concurrently with other erythropoiesis-stimulating agents (ESAs), including recombinant human erythropoietin (rHuEPO) drugs, has not been studied. The decision regarding whether or not to transition a patient from other ESAs to Varenzin-CA1 is ultimately the responsibility of the prescribing veterinarian.
On, the US Food and Drug Administration (FDA) conditionally approved Varenzin-CA1 (molidustat oral suspension) for the control
The results support the safety of Varenzin -CA1 when given in repeated 28-day treatment cycles. The results also indicate that most cats should only need to be off Varenzin -CA1 for at least 7 days before starting a new treatment cycle. User Safety. People exposed to Varenzin -CA1 should seek medical advice and may experience
Free Shipping on orders over $75. Low Price Match Guarantee. Varenzin-CA1 is a revolutionary new treatment in the fight against non-regenerative anemia in cats with CKD. veterinary medicine, Varenzin-CA1 stimulates a cat s body to create its own erythropoietin.
Elanco Animal Health Inc. received conditional approval from the Food and Drug Administration on Monday for its drug Varenzin-CA1 to treat anemia in cats with chronic kidney disease. The agency said Varenzin-CA1 helps to increase production of erythropoietin in the kidney, which in turn stimulates the bone marrow to produce more red blood cells.
Comments